Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jasper Capital
Redwood City, California, United States
- Ownership
- Private
- Employees
- ~32
- Development stage
- Other
01
Overview
Jasper's lead program, briquilimab, demonstrated positive responses in earlier dose cohorts in chronic spontaneous urticaria and chronic inducible urticaria, but recent data were confounded by an inactive drug lot, resulting in lower-than-expected responses in key Phase 1/2 cohorts and a halt to their asthma and severe combined immunodeficiency programs. New cohorts were initiated to determine robust dosing and resume progress in urticaria[2][3][4][6].
- Therapeutic areas
- HematologyImmunologyDermatologyPulmonology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
Beyond the preview
Go deeper on Jasper Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jasper Capital.